Johnson & Johnson Takes Legal Action Against Samsung Bioepis Over Stelara Biosimilar Contract Dispute

Johnson & Johnson and its subsidiary Janssen Biotech have initiated a lawsuit against Samsung Bioepis, alleging a breach of contract concerning a biosimilar version of their renowned biologic, Stelara. This legal action claims that Samsung Bioepis has violated the agreement’s stipulation that prohibits the company from assigning or sublicensing the patent rights to third parties. The lawsuit highlights the complexities of navigating biosimilar agreements, a growing area of interest as biologics continue to dominate the pharmaceutical market. For further details, the lawsuit can be explored through Law360.